Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1645-1653

  Hayashi, Yuya ^a   Mori, Yoshimasa ^a   Yamashita, Shogo ^a   Motoyama, Keiichi ^a   Higashi, Taishi ^a   Jono, Hirofumi ^b   Ando, Yukio ^b   Arima, Hidetoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

cyclodextrin; dendrimer; familial amyloidotic polyneuropathy; hepatocyte specific delivery; siRNA

Indexed keywords

ALPHA CYCLODEXTRIN; AMYLOID PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; DENDRIMER; LACTOSE; PREALBUMIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; CYTOTOXICITY; ENDOSOME; FAMILIAL AMYLOID POLYNEUROPATHY; GENE EXPRESSION; GLYCOSYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RNA INTERFERENCE; SUBSTITUTION REACTION;

ALPHA-CYCLODEXTRINS; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; BLOTTING, WESTERN; DENDRIMERS; FLOW CYTOMETRY; GENETIC VECTORS; HEP G2 CELLS; HEPATOCYTES; HUMANS; LACTOSE; MALE; MICE; MICROSCOPY, FLUORESCENCE; PREALBUMIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84862013499     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200654g     Document Type: Article

References (30)

1. Ando, Y.; Nakamura, M.; Araki, S. Transthyretin-related familial amyloidotic polyneuropathy. Arch. Neurol. 2005, 62, 1057-1062. (Pubitemid 41043725)
2. Benson, M. D.; Uemichi, T. Transthyretin amyloidosis. Amyloid 1996, 3, 44-56. (Pubitemid 126443497)
3. Benson, M. D.; Kincaid, J. C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007, 14, 277-282.
4. Connors, L. H.; Lim, A.; Prokaeva, T.; Roskens, V. A.; Costello, C. E. Tabulation of human transthyretin (TTR) variants. Amyloid 2003, 10, 160-184. (Pubitemid 37372400)
5. Westermark, P.; Benson, M. D.; Buxbaum, J. N. Amyloid fibril protein nomenclature-2002. Amyloid 2002, 99, 197-200.
6. Ando, Y. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med. Mol. Morphol. 2005, 38, 142-154. (Pubitemid 351543869)
7. Ando, Y.; Tanaka, Y.; Ando, E.; Yamashita, T.; Nishida, Y.; Tashima, K.; Suga, M.; Uchino, M.; Ando, M. Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet 1995, 354, 195-196.
8. Holmgren, G.; Steen, L.; Suhr, O.; Ericzon, B. G.; Groth, C. G.; Anderson, O.; Wallin, B. G.; Seymour, A.; Richardson, S.; Hawkins, P. N.; Pepys, M. B. Clinical improvement and amyloid regression after liver transplantation in hereditary transthretin amyloidosis. Lancet 1993, 341, 1113-1116. (Pubitemid 23125854)
9. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 1998, 391 (6669),806-11. (Pubitemid 28099681)
10. Castanotto, D.; Rossi, J. J. The promises and pitfalls of RNAinterference- based therapeutics. Nature 2009, 457 (7228), 426-33.
11. Kim, D. H.; Rossi, J. J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8 (3), 173-84.
12. Benson, M. D.; Kluve-Beckerman, B.; Zeldenrust, S. R.; Siesky, A. M.; Bodenmiller, D. M.; Showalter, A. D.; Sloop, K. W. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006, 33 (5), 609-18.
13. Semple, S. C.; Akinc, A.; Chen, J.; Sandhu, A. P.; Mui, B. L.; Cho, C. K.; Sah, D. W.; Stebbing, D.; Crosley, E. J.; Yaworski, E.; Hafez, I. M.; Dorkin, J. R.; Qin, J.; Lam, K.; Rajeev, K. G.; Wong, K. F.; Jeffs, L. B.; Nechev, L.; Eisenhardt, M. L.; Jayaraman, M.; Kazem, M.; Maier, M. A.; Srinivasulu, M.; Weinstein, M. J.; Chen, Q.; Alvarez, R.; Barros, S. A.; De, S.; Klimuk, S. K.; Borland, T.; Kosovrasti, V.; Cantley, W. L.; Tam, Y. K.; Manoharan, M.; Ciufolini, M. A.; Tracy, M. A.; de Fougerolles, A.; MacLachlan, I.; Cullis, P. R.; Madden, T. D.; Hope, M. J. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28 (2), 172-6.
14. Song, E.; Lee, S. K.; Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P.; Lieberman, J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 2003, 9 (3), 347-51. (Pubitemid 36362792)
15. Zhou, J.; Rossi, J. J. Aptamer-targeted cell-specific RNA interference. Silence 2010, 1 (1), 4.
16. Arima, H.; Yamashita, S.; Mori, Y.; Hayashi, Y.; Motoyama, K.; Hattori, K.; Takeuchi, T.; Jono, H.; Ando, Y.; Hirayama, F.; Uekama, K. In vitro and in vivo gene delivery mediated by Lactosylated dendrimer/α-cyclodextrin conjugates (G2) into hepatocytes. J. Controlled Release 2010, 146 (1), 106-17.
17. Motoyama, K.; Mori, Y.; Yamashita, S.; Hayashi, Y.; Jono, H.; Ando, Y.; Hirayama, F.; Uekama, K.; Arima, H. In vitro and in vivo gene delivery mediated by lactosylated dendrimer/α-cyclodextrin conjugates (G2) into hepatocytes. J. Inclusion Phenom. Macrocyclic Chem. 2011, 70, 333-338.
18. Baenziger, J. U.; Fiete, D. Structure of the complex oligosaccharides of fetuin. J. Biol. Chem. 1979, 254 (3), 789-95. (Pubitemid 9145936)
19. Tsutsumi, T.; Hirayama, F.; Uekama, K.; Arima, H. Evaluation of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J. Controlled Release 2007, 119 (3), 349-59. (Pubitemid 46770884)
20. Chiu, Y. L.; Ali, A.; Chu, C. Y.; Cao, H.; Rana, T. M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 2004, 11 (8), 1165-75. (Pubitemid 39138769)
21. Arima, H.; Tsutsumi, T.; Yoshimatsu, A.; Ikeda, H.; Motoyama, K.; Higashi, T.; Hirayama, F.; Uekama, K. Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. Eur. J. Pharm. Sci. 2011, 44 (3), 375-84.
22. Kedmi, R.; Ben-Arie, N.; Peer, D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 2010, 31 (26), 6867-75.
23. Malek, A.; Czubayko, F.; Aigner, A. PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J. Drug Targeting 2008, 16 (2), 124-39. (Pubitemid 351266549)
24. Xu, L.; Anchordoquy, T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J. Pharm. Sci. 2011, 100 (1), 38-52.
25. Davidson, B. L.; McCray, P. B., Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12 (5), 329-40.
26. Tiemann, K.; Rossi, J. J. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol. Med. 2009, 1 (3), 142-51.
27. Arima, H.; Kihara, F.; Hirayama, F.; Uekama, K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with α-, β-, and γ-cyclodextrins. Bioconjugate Chem. 2001, 12 (4), 476-84. (Pubitemid 32696220)
28. Kihara, F.; Arima, H.; Tsutsumi, T.; Hirayama, F.; Uekama, K. Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with α-cyclodextrin. Bioconjugate Chem. 2002, 13 (6), 1211-9. (Pubitemid 35420012)
29. Vasumathi, V.; Maiti, P. K. Complexation of siRNA with dendrimer: A molecular modeling approach. Macromolecules 2010, 43, 8264-74.
30. Roberts, J. C.; Bhalgat, M. K.; Zera, R. T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 1996, 30 (1), 53-65.